![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » DEBIOPHARM, AURIGENE TIE UP TO DEVELOP SELECTIVE COMPOUNDS FOR IMMUNO-ONCOLOGY TARGETS
DEBIOPHARM, AURIGENE TIE UP TO DEVELOP SELECTIVE COMPOUNDS FOR IMMUNO-ONCOLOGY TARGETS
The Switzerland-based Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based discovery services company, signed a research agreement to identify and develop compounds for two innovative immuno-oncology targets. Pharmabiz (http://pharmabiz.com/article/detnews.asp?articleid=33991ionid)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct